In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.